Biotechnology
Hinova Disclosed the Preclinical Results of HP518 (Oral AR PROTAC) at the 5th Annual TPD Summit
BOSTON, Oct. 29, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc. (STAR: 688302), a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today presented their preclinical results of ...
2022-10-29 05:30
9212
Nuevocor to Present Pre-clinical Data on its Gene Therapy Candidate for LMNA Dilated Cardiomyopathy at American Heart Association Scientific Sessions 2022
SINGAPORE, Oct. 28, 2022 /PRNewswire/ -- Nuevocor, a pre-clinical stage cardiac gene therapy company, announced today that it will present new preclinical data on its adeno-associated virus (AAV) gene therapy forLMNA dilated cardiomyopathy at the American Heart Association (AHA) Scientific Sessio...
2022-10-28 22:30
2889
LISCure Biosciences Announces Oral Presentation of New Drug Candidate for NASH at Upcoming AASLD The Liver Meeting 2022
The efficacy and mechanism of NASH microbiome-based therapy for liver fibrosis, steatosis, and inflammation have been confirmed in various animal models SEOUL, South Korea, Oct. 28, 2022 /PRNewswire/ -- LISCure Biosciences, a clinical-stage biopharmaceutical company developing microbe-oriented ne...
2022-10-28 21:00
2069
Pharming Announces European Medicines Agency (EMA) Validates its Marketing Authorisation Application under Accelerated Assessment for leniolisib
Marketing authorisation in the European Economic Area anticipated in H1 2023 LEIDEN, Netherlands, Oct. 28, 2022 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") (EURONEXT Amsterdam: PHARM / Nasdaq: PHAR) announces today that its Marketing Authorisation Application (MAA) for leni...
2022-10-28 13:00
4258
Acceptance Of The Application For Clinical Trial Of Recbio Novel Adjuvanted Recombinant Quadrivalent HPV Vaccine
TAIZHOU, China, Oct. 28, 2022 /PRNewswire/ -- Jiangsu Recbio Technology Co., Ltd. (the "Company", together with its subsidiaries, the "Group") is pleased to announce that, the Group has recently received a notice of acceptance from the National Medical Products Administration to accept the appli...
2022-10-28 11:10
3398
Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity
- Mean body weight loss of 11.1% in participants receiving once-weekly injections of 2.4 mg XW003 for 18 weeks - 88.5% and 57.7% of participants receiving 2.4 mg XW003 for 18 weeks achieved weight loss of≥5% and ≥10%, respectively - XW003 was safe and well tolerated, with an adverse event p...
2022-10-28 08:00
2547
NDA for New Second-Line Indication of CAR T-Cell Therapy Product YIKAIDA (Axicabtagene Ciloleucel Injection) Approved for CDE Review
Fosun Kite to Participate in the Fifth CIIE to Showcase New Options in Cell Therapy SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- October 24 brought good news from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) that the NDA for new second-line indication o...
2022-10-28 01:37
2276
Life sciences industry's highest achievers celebrated at prestigious Awards ceremony
AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards * Industry Leadership Award: Professors Steve Wilton AO and Sue Fletcher AO * Company of the Year: Telix Pharmaceuticals * Emerging Company of the Year: Fusetec AusBiotech Life Sciences Legacy Award: Dr Andrew Forrest AO a...
2022-10-27 22:39
3459
WuXi Biologics Provides Corporate Updates
SHANGHAI, Oct. 27, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today updated its recent corporate progress. Recent Business Milestone Despite the global dynamic situation and funding challeng...
2022-10-27 22:13
2567
Simcere Receives FDA Clearance of Investigational New Drug Application (IND) for Bi-functional Fusion Protein, SIM0237
Second US IND approval this year for the global pharmaceutical group NANJING, China and BOSTON, Oct. 27, 2022 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK), an innovative global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the com...
2022-10-27 21:25
2194
Kintor Pharma Announces Completion of Subject Enrollment and Dosing in Phase I Clinical Trial of AR-PROTAC(GT20029) in the US
SUZHOU, China, Oct. 27, 2022 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, today announced that the company has completed the enrollment and dosing of 120 subj...
2022-10-27 21:22
2182
Happiness Development Group Limited Regains Compliance with Nasdaq Minimum Bid Price Requirement
NANPING, China, Oct. 27, 2022 /PRNewswire/ -- Happiness Development Group Limited ("HAPP" or the "Company"),(NASDAQ: HAPP) announced today that on October 25, 2022, the Company received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC ("Nasdaq") n...
2022-10-27 20:00
2817
Cambrex to Invest $16.5 Million in New R&D Facility in Minneapolis, Minnesota and Expansion in Charles City, Iowa
EAST RUTHERFORD, N.J., Oct. 27, 2022 /PRNewswire/ -- Cambrex today announced it is investing in a new, 21,000-square-foot research and development facility in Minneapolis, Minnesota, expanding its capacity for small molecule development and manufacturing. Strategically located near the Minneapolis...
2022-10-27 18:00
2363
Tsinghua SIGS Virtual Open Day 2023 | Where your future starts
Attending an Open Day is a great opportunity to find out about the postgraduate programs we offer. Watch information sessions delivered by our faculties and get a deeper insight into our excellent programs. We are for you to provide all the information you want, including how we can help build yo...
2022-10-27 16:59
1774
Antengene to Host Research and Development Day on November 15th and 17th, 2022
* Virtual English Session: Tuesday, November 15 at 8:30 AM – 12:00 PM Eastern Time November 15 at 9:30 PM – November 16 at 1:00 AM Beijing Time * Hybrid Mandarin Session in Shanghai: Thursday, November 17 at 1:30 PM – 5:30 PM Beijing Time SHANGHAI and HONG KONG, Oct. 26, 2022 /PRNewswire/ -- An...
2022-10-27 11:07
3194
Telix Recognised as Company of the Year at AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards 2022
MELBOURNE, Australia, Oct. 27, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is today pleased to announce that it has been awarded Australian Company of the Year in the 2022 AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards, held today at t...
2022-10-27 10:23
3086
Cali Biosciences Announces Publications of Phase IIa Results of Long-Acting Ropivacaine (CPL-01)
CPL-01, for Non-Opioid Treatment of Post-Operative Pain, Garners Publication of Clinical Data in Abdominoplasty and Presentation of Preclinical Data in Bony and Soft-Tissue ModelsSupporting Pharmacokinetics and Safety SAN DIEGO, Oct. 26, 2022 /PRNewswire/ -- Cali Biosciences Co., Ltd. (hereinaft...
2022-10-27 10:07
1937
Forsea Attracts USD5.2M to Expand Cultivated Seafood, Without Harming Sea Life
Start-up pioneers organoid technology to make nature identical, cultured eel meat at cost parity REHOVOT, Israel, Oct. 27, 2022 /PRNewswire/ -- Forsea Foods, Ltd., a FoodTech start-up, is the first company to use organoid technology for culturing seafood products. With a goal of redressing the d...
2022-10-27 09:00
2260
SUCCESSFUL PASSING OF EU QP AUDIT ON TOT BIOPHARM'S COMMERCIAL PRODUCTION BASE FOR MONOCLONAL ANTIBODY DRUG SUBSTANCES AND ANTIBODY DRUG CONJUGATES
SUZHOU,China, Oct. 27, 2022 /PRNewswire/ -- TOT BIOPHARM International Company Limited (TOT BIOPHARM, Stock code: 1875.HK) has recently received a GMP compliance inspection report approved by aQualified Person ("QP") in the European Union ("EU") in respect of the manufacturing facilities and asso...
2022-10-27 08:00
2519
JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies
* Initial focus on accelerating development of 2seventy's MAGE-A4 program in solid tumors inChina SHANGHAI, China and CAMBRIDGE, Mass., Oct. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and comme...
2022-10-27 07:53
3757
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 314 media titles]
2024-11-21 10:30QDX Co-Founder Giuseppe Barca Awarded Prestigious Gordon Bell Prize, Pioneering Advancements in Drug Discovery Technology
[Picked up by 298 media titles]
2024-11-26 18:49Southeast Asian Consumers Raise Online Security Concerns, New GSMA Survey Shows
[Picked up by 294 media titles]
2024-11-26 13:00TAILG's First Flagship Store in Indonesia Grandly Opens
[Picked up by 283 media titles]
2024-11-22 21:59
MediSun Energy Raises $8.75M Seed Round with Vynn Capital to Drive MENA Expansion and Advance Osmotic Energy Innovation
[Picked up by 278 media titles]
2024-11-25 10:00
Most Read
Chinese path to modernization a model for Global South, experts say
2024-11-23 15:35
9561
Innovative technology and applications recognised with Hong Kong ICT Awards 2024
2024-11-23 02:02
6126
SUNLU Formnext 2024 Event Highlights: From Functional Filaments to FilaDryer E2
2024-11-23 21:00
6011
